Angiotensin II induces inflammation leading to cardiac remodeling

Frontiers in Bioscience

Volumn 17, Issue 1, 2012, Pages 221-231

  Jia, Lixin ^a,b   Li, Yulin ^a   Xiao, Chuanshi ^b   Du, Jie ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II; Cardiac Remodeling; Inflammation; Macrophage; Review

Indexed keywords

EID: 84860285260     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3923     Document Type: Article

References (91)

1. Touyz RM. Intracellular mechanisms involved in vascular remodeling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol 90(4):449-55 (2005) (Pubitemid 40980144)
2. Weber MA, Messerli FH. Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension 51(6):1465-7 (2008)
3. Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 27(2):92-8 (2002) (Pubitemid 34309394)
4. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Aslam S, Welch WJ, Wilcox CS. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 285(1):R117-24 (2003) (Pubitemid 36736508)
5. Szabó C, Pacher P, Zsengellér Z, Vaslin A, Komjáti K, Benkö R, Chen M, Mabley JG, Kollai M. Angiotensin IImediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol Med 10(1-6):28-35 (2004) (Pubitemid 39440318)
6. Yamamoto E, Kataoka K, Shintaku H, Yamashita T, Tokutomi Y, Dong YF, Matsuba S, Ichijo H, Ogawa H, Kim-Mitsuyama S. Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure. Arterioscler Thromb Vasc Biol 27(12):2569-75 (2007) (Pubitemid 350158907)
7. Rizzoni D, Rosei EA. Small artery remodeling in diabetes mellitus. Nutr Metab Cardiovasc Dis 19(8):587-92 (2009)
8. Alvarez A, Cerda-Nicolas M, Naim Abu Nabah Y, Mata M, Issekutz AC, Panes J, Lobb RR, Sanz MJ. Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood 104(2):402-8 (2004) (Pubitemid 38900021)
9. Piqueras L, Kubes P, Alvarez A, O'Connor E, Issekutz AC, Esplugues JV, Sanz MJ. Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation. Circulation 102(17):2118-23 (2000)
10. Larsson PT, Schwieler JH, Wallen NH. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul Fibrinolysis 11(1):61-9 (2000) (Pubitemid 30090905)
11. Kuebler WM. Selectins revisited: the emerging role of platelets in inflammatory lung disease. J Clin Invest 116(12):3106-8 (2006) (Pubitemid 44878623)
12. Wang HB, Wang JT, Zhang L, Geng ZH, Xu WL, Xu T, Huo Y, Zhu X, Plow EF, Chen M, Geng JG. P-selectin primes leukocyte integrin activation during inflammation. Nat Immunol 8(8):882-92 (2007) (Pubitemid 47099040)
13. Ieda M, Tsuchihashi T, Ivey KN, Ross RS, Hong TT, Shaw RM, Srivastava D. Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Dev Cell 16(2):233-44 (2009)
14. Xu J, Carretero OA, Liao TD, Peng H, Shesely EG, Liu TS, Yang JJ, Reudelhuber TL, Yang XP. Local angiotensin II aggravates cardiac remodeling in hypertension. Am J Physiol Heart Circ Physiol 299(5):H1328-38 (2010)
15. Ishibashi M, Hiasa K, Zhao Q, Inoue S, Ohtani K, Kitamoto S, Tsuchihashi M, Sugaya T, Charo IF, Kura S, Tsuzuki T, Ishibashi T, Takeshita A, Egashira K. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res. 94(9):1203-10 (2004) (Pubitemid 38659633)
16. Wolf G, Ziyadeh FN, Thaiss F, Tomaszewski J, Caron RJ, Wenzel U, Zahher G, Helmchen U, Stahl RA. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest 100(5):1047-58 (1997) (Pubitemid 27386288)
17. Nabah YN, Mateo T, Estelles R, Mata M, Zagorski J, Sarau H, Cortijo J, Morcillo EJ, Jose PJ, Sanz MJ. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation 110(23):3581-6 (2004) (Pubitemid 39612574)
18. Haudek SB, Xia Y, Huebener P, Lee JM, Carlson S, Crawford JR, Pilling D, Gomer RH, Trial J, Frangogiannis NG, Entman ML. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A 103(48):18284-9 (2006) (Pubitemid 44871650)
19. Zhang J, Silva T, Yarovinsky T, Manes TD, Tavakoli S, Nie L, Tellides G, Pober JS, Bender JR, Sadeghi MM. VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling. Circ Res 107(3):408-17 (2010)
20. Catela C, Kratsios P, Hede M, Lang F, Rosenthal N. Serum and glucocorticoid-inducible kinase 1 (SGK1) is necessary for vascular remodeling during angiogenesis. Dev Dyn 239(8):2149-60 (2010)
21. Strieter RM, Gomperts BN, Keane MP. The role of CXC chemokines in pulmonary fibrosis. J Clin Invest. 117(3):549-56 (2007) (Pubitemid 46348509)
22. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol. 28(11):1950-9 (2008)
23. Kodali R, Hajjou M, Berman AB, Bansal MB, Zhang S, Pan JJ, Schecter AD. Chemokines induce matrix metalloproteinase-2 through activation of epidermal growth factor receptor in arterial smooth muscle cells. Cardiovasc Res. 69(3):706-15 (2006) (Pubitemid 43139733)
24. Abu Nabah YN, Losada M, Estelles R, Mateo T, Company C, Piqueras L, Lopez-Gines C, Sarau H, Cortijo J, Morcillo EJ, Jose PJ, Sanz MJ. CXCR2 blockade impairs angiotensin IIinduced CC chemokine synthesis and mononuclear leukocyte infiltration. Arterioscler Thromb Vasc Biol. 27(11):2370-6 (2007) (Pubitemid 350203952)
25. Abd Alla J, Langer A, Elzahwy SS, Arman-Kalcek G, Streichert T, Quitterer U. Angiotensin-converting enzyme inhibition down-regulates the pro-atherogenic chemokine receptor 9 (CCR9)-chemokine ligand 25 (CCL25) axis. J Biol Chem 285(30):23496-505 (2010)
26. Wei L. Immunological aspect of cardiac remodeling: T lymphocyte subsets in inflammation-mediated cardiac fibrosis. Exp Mol Pathol. (2010)
27. Nicoletti A, Michel JB. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res. 41(3):532-43 (1999) (Pubitemid 29130617)
28. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colonystimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol. 25(10):2106-13 (2005) (Pubitemid 41416308)
29. Tieu BC, Lee C, Sun H, Lejeune W, Recinos A, 3rd, Ju X, Spratt H, Guo DC, Milewicz D, Tilton RG, Brasier AR. An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. J Clin Invest. 119(12):3637-51 (2009)
30. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 3(1):23-35 (2003) (Pubitemid 37328697)
31. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schutz G, Lumeng CN, Mortensen RM. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest. 120(9):3350-64 (2010)
32. Aki K, Shimizu A, Masuda Y, Kuwahara N, Arai T, Ishikawa A, Fujita E, Mii A, Natori Y, Fukunaga Y, Fukuda Y. ANG II receptor blockade enhances anti-inflammatory macrophages in anti-glomerular basement membrane glomerulonephritis. Am J Physiol Renal Physiol. 298(4):F870-82 (2010)
33. Shen XZ, Li P, Weiss D, Fuchs S, Xiao HD, Adams JA, Williams IR, Capecchi MR, Taylor WR, Bernstein KE. Mice with enhanced macrophage angiotensin- converting enzyme are resistant to melanoma. Am J Pathol. 170(6):2122-34 (2007) (Pubitemid 47339284)
34. Kohlstedt K, Trouvain C, Namgaladze D, Fleming I. Adipocyte-derived lipids increase angiotensin-converting enzyme (ACE) expression and modulate macrophage phenotype. Basic Res Cardiol. (2010)
35. Balsari A, Marolda R, Gambacorti-Passerini C, Sciorelli G, Tona G, Cosulich E, Taramelli D, Fossati G, Parmiani G, Cascinelli N. Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study. Cancer Immunol Immunother. 21(2):148-55 (1986) (Pubitemid 16155062)
36. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 204(10):2449-60 (2007) (Pubitemid 47529329)
37. Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, Weyand C, Harrison DG. Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol. 296(2):R208-16 (2009)
38. Vinh A, Chen W, Blinder Y, Weiss D, Taylor WR, Goronzy JJ, Weyand CM, Harrison DG, Guzik TJ. Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation 122(24):2529-37 (2010)
39. Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, Fujita T. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 42(1):31-8 (2003) (Pubitemid 36842233)
40. Yu Q, Watson RR, Marchalonis JJ, Larson DF. A role for T lymphocytes in mediating cardiac diastolic function. Am J Physiol Heart Circ Physiol. 289(2):H643-51(2005) (Pubitemid 41129379)
41. Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, Harrison DG. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 55(2):500-7 (2010)
42. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, Phillips LK, Goldstein MJ, Bhat R, Raine CS, Sobel RA, Steinman L. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1-and TH17-mediated autoimmunity. Proc Natl Acad Sci U S A. 106(35):14948-53 (2009)
43. Kvakan H, Kleinewietfeld M, Qadri F, Park JK, Fischer R, Schwarz I, Rahn HP, Plehm R, Wellner M, Elitok S, Gratze P, Dechend R, Luft FC, Muller DN. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 119(22):2904-12 (2009)
44. Bataller R, Gabele E, Schoonhoven R, Morris T, Lehnert M, Yang L, Brenner DA, Rippe RA. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol. 285(3):G642-51 (2003) (Pubitemid 37021824)
45. Recinos A, 3rd, LeJeune WS, Sun H, Lee CY, Tieu BC, Lu M, Hou T, Boldogh I, Tilton RG, Brasier AR. Angiotensin II induces IL-6 expression and the Jak-STAT3 pathway in aortic adventitia of LDL receptor-deficient mice. Atherosclerosis 194(1):125-33 (2007) (Pubitemid 47464314)
46. Kang YM, Ma Y, Zheng JP, Elks C, Sriramula S, Yang ZM, Francis J. Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin IIinduced hypertension. Cardiovasc Res. 82(3):503-12 (2009)
47. Rojas M, Zhang W, Lee DL, Romero MJ, Nguyen DT, Al-Shabrawey M, Tsai NT, Liou GI, Brands MW, Caldwell RW, Caldwell RB. Role of IL-6 in angiotensin II-induced retinal vascular inflammation. Invest Ophthalmol Vis Sci. 51(3):1709-18 (2010)
48. Gurantz D, Cowling RT, Varki N, Frikovsky E, Moore CD, Greenberg BH. IL-1beta and TNF-alpha upregulate angiotensin II type 1 (AT1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart. J Mol Cell Cardiol. 38(3):505-15 (2005) (Pubitemid 40331941)
49. Kadokami T, Frye C, Lemster B, Wagner CL, Feldman AM, McTiernan CF. Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation 104(10):1094-7 (2001) (Pubitemid 32830389)
50. Sun M, Dawood F, Wen WH, Chen M, Dixon I, Kirshenbaum LA, Liu PP. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation 110(20):3221-8 (2004) (Pubitemid 39525069)
51. Monden Y, Kubota T, Inoue T, Tsutsumi T, Kawano S, Ide T, Tsutsui H, Sunagawa K. Tumor necrosis factor-alpha is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction. Am J Physiol Heart Circ Physiol. 293(1):H743-53 (2007) (Pubitemid 47105137)
52. Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, Reddy A, Frangogiannis NG. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol. 173(1):57-67 (2008) (Pubitemid 351947955)
53. Coles B, Fielding CA, Rose-John S, Scheller J, Jones SA, O'Donnell VB. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am J Pathol. 171(1):315-25 (2007) (Pubitemid 47339248)
54. Ashizawa N, Graf K, Do YS, Nunohiro T, Giachelli CM, Meehan WP, Tuan TL, Hsueh WA. Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. J Clin Invest. 98(10):2218-27 (1996) (Pubitemid 26394194)
55. Collins AR, Schnee J, Wang W, Kim S, Fishbein MC, Bruemmer D, Law RE, Nicholas S, Ross RS, Hsueh WA. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J Am Coll Cardiol. 43(9):1698-705 (2004) (Pubitemid 38561355)
56. Matsui Y, Jia N, Okamoto H, Kon S, Onozuka H, Akino M, Liu L, Morimoto J, Rittling SR, Denhardt D, Kitabatake A, Uede T. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 43(6):1195-201 (2004) (Pubitemid 38691740)
57. Tamura K, Okazaki M, Tamura M, Kanegae K, Okuda H, Abe H, Nakashima Y. Synergistic interaction of integrin and angiotensin II in activation of extracellular signalregulated kinase pathways in vascular smooth muscle cells. J Cardiovasc Pharmacol. 38 Suppl 1:S59-62 (2001) (Pubitemid 33104685)
58. Yu Q, Vazquez R, Khojeini EV, Patel C, Venkataramani R, Larson DF. IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Am J Physiol Heart Circ Physiol. 297(1):H76-85 (2009)
59. Ogawa S, Kobori H, Ohashi N, Urushihara M, Nishiyama A, Mori T, Ishizuka T, Nako K, Ito S. Angiotensin II Type 1 Receptor Blockers Reduce Urinary Angiotensinogen Excretion and the Levels of Urinary Markers of Oxidative Stress and Inflammation in Patients with Type 2 Diabetic Nephropathy. Biomark Insights. 4:97-102 (2009)
60. Zemse SM, Hilgers RH, Webb RC. Interleukin-10 counteracts impaired endothelium-dependent relaxation induced by ANG II in murine aortic rings. Am J Physiol Heart Circ Physiol. 292(6):H3103-8 (2007) (Pubitemid 47084565)
61. Didion SP, Kinzenbaw DA, Schrader LI, Chu Y, Faraci FM. Endogenous interleukin-10 inhibits angiotensin II-induced vascular dysfunction. Hypertension 54(3):619-24 (2009)
62. Laura PA, Michela DR, Silvia M, Marcello P, Gerarda P, Alberto A, Luca P. Pro/Anti-inflammatory cytokine imbalance in postischemic left ventricular remodeling. Mediators Inflamm. (2010)
63. Ma Y, Zhang L, Peng T, Cheng J, Taneja S, Zhang J, Delafontaine P, Du J. Angiotensin II stimulates transcription of insulin-like growth factor I receptor in vascular smooth muscle cells: role of nuclear factor-kappaB. Endocrinology 147(3):1256-63 (2006) (Pubitemid 43244358)
64. Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, Oettgen P. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest. 115(9):2508-16 (2005) (Pubitemid 41266213)
65. Nishida M, Kitajima N, Saiki S, Nakaya M, Kurose H. Regulation of Angiotensin II receptor signaling by cysteine modification of NF-kappaB. Nitric Oxide. (2010)
66. Wang HD, Xu S, Johns DG, Du Y, Quinn MT, Cayatte AJ, Cohen RA. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res. 88(9):947-53 (2010)
67. Whaley-Connell A, Govindarajan G, Habibi J, Hayden MR, Cooper SA, Wei Y, Ma l, Qazi M, Link D, Karuparthi PR, Stump C, Ferrario C, Sowers JR. Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. Am J Physiol Endocrinol Metab. 293(1):E355-63 (2007) (Pubitemid 47105951)
68. Oudit GY, Kassiri Z, Patel MP, Chappell M, Butany J, Backx PH, Tsushima RG, Scholey JW, Khokha R, Penninger JM. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res. 75(1):29-39 (2007) (Pubitemid 46873522)
69. Usui M, Egashira K. Angiotensin II receptor and oxidative stress. Nippon Rinsho. 60(10):1893-7 (2002)
70. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 86(5):494-501 (2000) (Pubitemid 30165039)
71. Oudot A, Vergely C, Ecarnot-Laubriet A, Rochette L. Angiotensin II activates NADPH oxidase in isolated rat hearts subjected to ischaemia- reperfusion. Eur J Pharmacol. 462(1-3):145-54 (2003) (Pubitemid 36183746)
72. Li JM, Shah AM. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem. 278(14):12094-100 (2003) (Pubitemid 36800187)
73. McAllister-Lucas LM, Jin X, Gu S, Siu K, McDonnell S, Ruland J, Delekta PC, Van Beek M, Lucas PC. The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis. J Biol Chem. 285(34):25880-4 (2010)
74. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, Harrison DG, Medford RM. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation 100(11):1223-9 (1999) (Pubitemid 29426599)
75. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res. 102(4):488-96 (2008) (Pubitemid 351651106)
76. Zahradka P, Werner JP, Buhay S, Litchie B, Helwer G, Thomas S. NF-kappaB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. J Mol Cell Cardiol. 34(12):1609-21 (2002) (Pubitemid 35454476)
77. Sarman B, Skoumal R, Leskinen H, Rysa J, Ilves M, Soini Y, Tuukkanen J, Pikkarainen S, Lako-Futo Z, Papp L, deChatel R, Toth M, Ruskoaho H, Szokodi I. Nuclear factor-kappaB signaling contributes to severe, but not moderate, angiotensin II-induced left ventricular remodeling. J Hypertens. 25(9):1927-39 (2007) (Pubitemid 47356635)
78. Masur SK, Dewal HS, Dinh TT, Erenburg I, Petridou S. Myofibroblasts differentiate from fibroblasts when plated at low density. Proc Natl Acad Sci U S A. 93(9):4219-23 (1996) (Pubitemid 26144266)
79. Haudek SB, Cheng J, Du J, Wang Y, Hermosillo-Rodriguez J, Trial J, Taffer GE, Entman ML. Monocytic fibroblast precursors mediate fibrosis in angiotensin-IIinduced cardiac hypertrophy. J Mol Cell Cardiol. 49(3):499-507 (2010)
80. Arciniegas E, Frid MG, Douglas IS, Stenmark KR. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 293(1):L1-8 (2007) (Pubitemid 47080705)
81. Sopel MJ, Rosin NL, Lee TD, Legare JF. Myocardial fibrosis in response to Angiotensin II is preceded by the recruitment of mesenchymal progenitor cells. Lab Invest. (2010)
82. Campbell SE, Janicki JS, Weber KT. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol. 27(8):1545-60 (1995)
83. Marshall RP, McAnulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am J Respir Crit Care Med. 161(6):1999-2004 (2000) (Pubitemid 30418143)
84. Gerasimovskaya EV, Tucker DA, Stenmark KR. Activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin is necessary for hypoxiainduced pulmonary artery adventitial fibroblast proliferation. J Appl Physiol. 98(2):722-31 (2005) (Pubitemid 40129988)
85. Lijnen PJ, Petrov VV, Fagard RH. Angiotensin IIinduced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors. J Renin Angiotensin Aldosterone Syst. 2(2):117-22 (2001) (Pubitemid 33686750)
86. Swaney JS, Roth DM, Olson ER, Naugle JE, Meszaros JG, Insel PA. Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase. Proc Natl Acad Sci U S A. 102(2):437-42 (2005) (Pubitemid 40116785)
87. Tian B, Liu J, Bitterman P, Bache RJ. Angiotensin II modulates nitric oxide-induced cardiac fibroblast apoptosis by activation of AKT/PKB. Am J Physiol Heart Circ Physiol. 285(3):H1105-12 (2003) (Pubitemid 37048166)
88. Pattacini L, Casali B, Boiardi L, Pipitone N, Albertazzi L, Salvarani C. Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-kappaB pathway. Rheumatology (Oxford). 46(8):1252-7 (2007) (Pubitemid 47244496)
89. Wu LL, Yang N, Roe CJ, Cooper ME, Gilbert RE, Atkins RC, Lan HY. Macrophage and myofibroblast proliferation in remnant kidney: role of angiotensin II. Kidney Int Suppl. 63:S221-5 (1997) (Pubitemid 28020477)
90. Guy JL, Lambert DW, Turner AJ, Porter KE. Functional angiotensin- converting enzyme 2 is expressed in human cardiac myofibroblasts. Exp Physiol. 93(5):579-88 (2008) (Pubitemid 351595051)
91. Small EM, Thatcher JE, Sutherland LB, Kinoshita H, Gerard RD, Richardson JA, Dimaio JM, Sadek H, Kuwahara K, Olson EN. Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction. Circ Res. 107(2):294-304 (2010)